Member Info for AVCT

Alternatively it may be a concious decision to have just one RNS so as not to highlight the month or so to fully recruit for each cohort.

Moron

noun

a stupid person.

"we can't let these thoughtless morons get away with mindless vandalism every weekend"

Think his handle on here is “AVCT”. - correct

Numbers into perspective? It’s called coincidence. - wtf does that mean ?

@JT I think you may well be right - LG certainly seem to be taking rheir time with affimers

point licensed from tufts originaly for a reason ?

What work does a biotech do prior to "preclinical" that would take that sort of time?

Thanks JT - I stand corrected

referencing two other recent AGM notices BP and HSBC you are correct that they also include a standard looking 66.66% pre-emptive authorisation resolution.

the point remains that with the sought authorisation for issuance of upto 240m additional shares the Avacta BOD have super flexibilty for potential negotiations we all feel they are likely to be undertaking at the moment.

Clearly if thought desireable by the BOD to issue shares to whoever, the actual number issued would be a function of price ( which could be practicaly any figure ) and the total amount they wish to raise by that means.

An additional tool for SB in his negotiations.

"There is very little discussion about this on X."

Yes because it doesn't fit the twitterati takeover agenda.

Imo they have a plan and are seeking to strengthen their negotiating position ahead of negotiations on a collaboration.

Smoothing the way for wide ranging flexibile negotiations and showing they have approval for other options if necessary.

"Avacta propose to issue a huge number of shares and no one here has an opinion ."

They are seeking permission for a rights issue - not proposing one.

Two completely different things.

Such authority IS NOT "bog standard"

"Because it is the same resolution every year. Not just for Avacta but a bog standard listed company resolution. It's not that they will do it, it's just giving them the power to do it, if the BOD feels it's necessary."

40% "bog standard" - I don't think so

Care to post any examples ?

Imo 2w updates won't have much lasting effect on SP as in themselves they don't involve any money and by and large are most likely already well discounted as expected to be good.

"based on the new COS risk criteria which is pretty standard company policy for all early stage trials. (Regardless of Biopsy data) currently sitting at 10%"

Presumably you didn't see the COS used in the DB hatchet job!

"Looks like their market cap is only $3.2m so a cheap route to getting a Nasdaq listing if that's what is wsnted..."

Rofl

"£5 is £18 billion"

Think you need a new calculator rofl

"..but the sooner we get AVA6000 to market the better .."

This imo is not the major driver, but rather the broader commercialisation of the Pecision platform which we are tolď is now proven and ready to be commercialised subject to negotiation.

"But I believe that in fact they cannot move on to the 2nd cohort until the 1st cohort finishes. The "parallel" refers to the fact that they can dose all 3 patients in a cohort at the same time."

Wouldn't it be great if #AVCT spelt this out explicitly.

"You are all assuming he was pushed...well maybe as a scientist..."

or maybe it just makes sense allround for AS to have gone now, take his pay off and his exercised option shares with him.

With a fair wind He'll be quids in in the long run - look at the after tax if you know how.

I'VE been considering the taxation of options and wonder if the final decision by AS to leave was taken on 9th April and a combination of valuations at the moment and £M severance package may actually mean that everyone, including AS are reasonably happy with the situation.

Hmmmm

Look more closely at their news flow

https://perspectivetherapeutics.com/newsroom/press-release?i=130069

Strategic agreement and investment in January plus couple of further dilutive raises shortly after totalling 50% is dilution ( I've not done the exact numbers )

It's the way they do it in US they raise and dilute ti increase the overall pie.

The AVCT model upto now has been to try and minimise dilution - there are pros and cons of each method.

Ultimately the moment of truth for either method is when external investment interest from BP is attracted - the jurys out on that at the moment, but maybe not for too much longer.

"With regard to CFO he is also the company secretary -so if replaced might need to hire two people ."

Rofl pmsl - one will suffice !

Don't know - would have to refresh memory if going from vested option to exercised required disclosure.